MOBIDIAG
Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address infectious diseases, antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has received CE-IVD markings for its Novodiag® COVID-19 and Amplidiag® COVID-19 molecular diagnostic tests for the early detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19).
These tests complement the Company’s already available antibody test, Anti-SARS-CoV-2 Rapid Test , that Mobidiag is distributing from its joint venture partner in China, Autobio Diagnostics. Mobidiag is now able to commercially offer a comprehensive diagnostic solution for novel coronavirus infections for hospital and lab based settings.
Due to the high demand for diagnostic devices and tests globally, Mobidiag has ensured that its supply chain and manufacturing capabilities are robust and able to support its customers. This includes, for example, the sourcing and acquisition of various consumables to cover the complete workflow from sample collection to the results (e.g. inhouse production of enzymes and the development of our proprietary mNAT™ Medium sample buffer and collection tubes).
Tuomas Tenkanen, CEO of Mobidiag, said, “With the CE-IVD mark approvals for our Novodiag COVID-19 and Amplidiag COVID-19 molecular diagnostic tests and our distribution of the Anti-SARS-CoV-2 Rapid antibody test, Mobidiag is now able to provide a complete diagnostic solution for the detection of COVID-19 infections across the life cycle of the virus.”
“Mobidiag has leveraged its existing technologies and expertise, including supply chain management and manufacturing, to ensure we are able to deliver a full range of diagnostic solutions to our customers.”
The Novodiag® COVID-19 and Amplidiag® COVID-19 molecular diagnostic tests are able to rapidly and reliably detect COVID-19 infections at an early stage in patients with signs and symptoms of respiratory infection. They have already earlier been granted emergency use authorisation in Finland, Sweden and France. The tests have been designed using dual targets of SARS-CoV-2 (orf1ab & N genes) to include at least one conserved region and one specific region to mitigate the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses.
The Novodiag® COVID-19 assay allows qualitative determination of SARS-CoV-2 (orf1ab and N genes) directly from nasopharyngeal swabs. The test operates using the Novodiag® rapid ‘sample-in, result-out’ system, allowing the on demand fully automated detection of COVID-19 in approximately 1 hour. In addition, Novodiag® solution is a closed system which ensures the protection of laboratory staff and healthcare professionals from possible contamination. The user-friendly nature of the system means that the Novodiag® system can also be used in high risk and hard-to-reach areas and decentralized settings without the need for highly trained personnel.
The Amplidiag® COVID-19 assay complements the Novodiag® COVID-19 on demand test. Based on well-established high-throughput qualitative PCR technology, 48 samples can be processed in less than three hours while running on Mobidiag’s Amplidiag® Easy platform , which enables to clinicians an optimized sample screening process with automated DNA/RNA extraction and PCR plate setup.
In addition to these molecular tests, Mobidiag is distributing an antibody test allowing qualitative determination of Anti-SARS-CoV-2 (IgG and IgM antibodies of SARS-CoV-2) in human serum, plasma or whole blood in less than 15 minutes without any instrumentation. The Anti-SARS-CoV-2 Rapid Test is manufactured by Mobidiag’s joint venture partner in China, Autobio Diagnostics.
Please note that these tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Please follow the recommended processes and guidance for your location if you believe you could be infected by SARS-CoV-2.
Notes to editors
About Mobidiag Ltd
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose fast, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200601005614/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NuORDER by Lightspeed Extends Partnership with Nordstrom as Retailer Invests in Data-Driven Wholesale Strategies29.10.2025 12:05:00 CET | Press release
NuORDER by Lightspeed, a leading global commerce platform that enables retailers and brands to connect, collaborate, and make smarter buying decisions, today announced Nordstrom is strengthening its partnership with NuORDER by Lightspeed. NuORDER will play a larger role in Nordstrom’s end-to-end data and integration program to enable Nordstrom to further improve their merchandise assortment and customer experience. By creating a universal catalog of product, category, sizing data, and imagery, NuORDER helps Nordstrom operate more efficiently at scale by reducing manual processes and accelerating buying cycles. Today, NuORDER collects over 50 data points per item. As Nordstrom develops AI-powered processes to get merchandise to customers more efficiently, NuORDER will increase data capture to support AI-driven forecasting, product recommendations, and personalization. “Collecting comprehensive product data from thousands of brands is time-intensive, costly, and requires extensive collab
Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors29.10.2025 11:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective immediately. Dr. Jonas brings more than three decades of leadership in pharmaceutical research and development, with a particular focus on neuroscience. As part of this Board transition, Thomas Lönngren will retire from his position on the Board at the end of December after more than six years of service. Mr. Lönngren has been an invaluable counselor across the company’s achievements, including the advancement of the COMP360 program and transition from an early-stage to late-stage clinical company. “With Compass leading the field of psychedelics and looking ahead to potential commercialization for COMP360, we are grateful to have Dr. Jonas’ extensive experience in neuroscience, an area in which he has consistently driven breakthroughs in treatment,” s
Tecnotree Maintains Momentum with Sixth Consecutive Quarter of Profit and Cash Flow29.10.2025 10:12:00 CET | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, announced today its Q3 2025 results, summarizing financial performance year-to-date ending 30 September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029815979/en/ Tecnotree Maintains Momentum with Sixth Consecutive Quarter of Profit and Cash Flow Year-to-Date Financial Highlights as of Q3 2025: Positive free cash flow EUR 3.2 (–2.2) million, sixth consecutive quarter of cash-positive operations. Revenue in constant currency EUR 56.6 (54.0) million, +4.8%. EBIT in constant currency EUR 14.9 (13.0) million, +15.0%. Annual recurring revenue EUR 25.1 (23.2) million, +8%. Order backlog EUR 105.5 (75.1) million, +40%. Commenting on the results for the third quarter of 2025, Padma Ravichander, CEO of Tecnotree, says: “Tecnotree’s Q3 2025 results reflect our disciplined focus on profitable order book execution, with year-to
Domaine Worldwide and Shopify Launch Enterprise Platform Migration Initiative Across Europe29.10.2025 10:00:00 CET | Press release
Domaine Worldwide, the leading global Shopify design and development partner, announced the launch of its European Platform Migrations partnership with Shopify today. The initiative positions Domaine as the go-to commerce partner for enterprise-level brands across the UK, DACH, and BENELUX regions looking to migrate to Shopify’s scalable, commerce-ready infrastructure. As enterprise organizations across Europe face the challenge of modernizing legacy systems, this campaign highlights the combined power of Domaine’s migration expertise and Shopify’s enterprise-grade flexibility—offering brands a seamless path to improved performance, agility, and long-term growth. “For enterprise retailers, platform migration is no longer just a technical decision—it’s a strategic one. For some, it's become a strategic imperative,” said Marko Bon, Co-founder and President of Domaine. “We’ve seen first-hand how a migration to Shopify is a foundational step in digital business transformation, unlocking st
MOPIC Unveils 32-Inch Autostereoscopic 3D Display for Endoscopic and Microscope Applications Capable of Realistic Depth and Immersive Visualization29.10.2025 09:00:00 CET | Press release
MOPIC, a leading developer of autostereoscopic 3D display technology, has unveiled its 32-inch autostereoscopic 3D display designed for 3D endoscopic and microscope imaging systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029144650/en/ MOPIC unveiled its 32-inch autostereoscopic 3D display capable of lifelike depth and spatial perception without the need for 3D glasses (Photo: MOPIC) The new product reproduces lifelike depth and spatial perception without the need for 3D glasses, setting a new benchmark for medical visualization and education. Optimized 3D Solution for Medical Training and Research The 32-inch autostereoscopic 3D display combines a display with an integrated 3D lens, an eye-tracking camera, and real-time 3D rendering software provided as an SDK. It supports standard stereo formats such as Side-by-Side, and can be directly connected to existing endoscopes or microscope systems through 3D software in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom